Byotrol PLC
LSE:BYOT
Intrinsic Value
Byotrol Plc engages in the development, manufacture, and sale of anti-microbial products. [ Read More ]
The intrinsic value of one
BYOT
stock under the Base Case scenario is
2.56
GBX.
Compared to the current market price of 0.125 GBX,
Byotrol PLC
is
Undervalued by 95%.
Byotrol PLC's market capitalization is 567.4k GBX.
BYOT stock price is 0.125 GBX.
BYOT stock price (0.125 GBX) is 95% less than its Intrinsic Value (2.56 GBX).
BYOT stock price (0.125 GBX) is 93% less than its Relative Value (1.728 GBX). Open Relative Valuation
BYOT.
BYOT has positive Net Debt. This means that the company has more debt (962k GBP) than cash and short-term investments (508k GBP).
BYOT's Altman Z-Score is equal to 2.31.
BYOT's Revenue has dropped by 19% over the past 12 months.
BYOT's ROE (Return on Equity) has significantly decreased in the last 3 years from 12% to -32%.
BYOT's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 16% to -26%.
BYOT has positive Gross Profit for the last twelve months.
BYOT has negative Operating Income for the last twelve months.
BYOT has negative Net Income for the last twelve months.
BYOT's ROE (Return on Equity) for the past 12 months is negative and is equal to -32%.
BYOT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -26%.
BYOT's short-term assets (2m GBP) exceed its short-term liabilties (1m GBP).
BYOT has negative three-year average ROIC (Return on Invested Capital): -4%. The company is not efficient at using invested capital to generate operating income.
BYOT has negative three-year average ROE (Return on Equity): -9%. The company is not efficient at transforming stockholders' equity into net income.
BYOT's Revenue has been falling by 30% per year for the last 3 years.
BYOT has negative Free Cash Flow for the last twelve months.
BYOT's long-term assets (7m GBP) exceed its long-term liabilties (2m GBP).
BYOT's D/E (Debt to Equity) is very low and is equal to 0.2.
BYOT doesn't generate enough operating income (-2m GBP) to safely cover interest payments on its debt (106k GBP).
Fundamental Analysis
Byotrol PLC
Balance Sheet Decomposition
Byotrol PLC
| Current Assets | 2.4m |
| Cash & Short-Term Investments | 508k |
| Receivables | 1.2m |
| Other Current Assets | 632k |
| Non-Current Assets | 4.8m |
| PP&E | 59k |
| Intangibles | 3.2m |
| Other Non-Current Assets | 1.5m |
| Current Liabilities | 1m |
| Accounts Payable | 1m |
| Other Current Liabilities | 8k |
| Non-Current Liabilities | 1.2m |
| Long-Term Debt | 962k |
| Other Non-Current Liabilities | 266k |
Earnings Waterfall
Byotrol PLC
|
Revenue
|
4.4m
GBP
|
|
Cost of Revenue
|
-2.5m
GBP
|
|
Gross Profit
|
1.9m
GBP
|
|
Operating Expenses
|
-3.6m
GBP
|
|
Operating Income
|
-1.7m
GBP
|
|
Other Expenses
|
-145k
GBP
|
|
Net Income
|
-1.9m
GBP
|
Free Cash Flow Analysis
Byotrol PLC
What is Free Cash Flow?
BYOT Profitability Score
Profitability Due Diligence
Byotrol PLC's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Byotrol PLC's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
BYOT Solvency Score
Solvency Due Diligence
Byotrol PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Byotrol PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BYOT Price Targets Summary
Byotrol PLC
Shareholder Return
BYOT Price
Byotrol PLC
| Average Annual Return | 51.23% |
| Standard Deviation of Annual Returns | 169.93% |
| Max Drawdown | -99% |
| Market Capitalization | 567.4k GBX |
| Shares Outstanding | 453 890 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Byotrol PLC
Country
Industry
Market Cap
Dividend Yield
Description
Byotrol Plc engages in the development, manufacture, and sale of anti-microbial products. The company is headquartered in Chester, Cheshire and currently employs 39 full-time employees. The company went IPO on 2005-07-06. The firm sells products based on its anti-microbial technology to in the United Kingdom. The firm operates through two segments: Professional (including human health, animal health, facilities management, and food and beverage) and Consumer (including household, skin care and pet care). Its products category includes Coronavirus, Medical Device Cleaning and Disinfection, Defra Tested, Surface Disinfection, Reprocessing of Instruments, Skin Disinfection, Odor Control, Pet Retail, Body Spills and Ancillaries. Its Coronavirus products comprises of CHEMGENE HLD4H UNIVERSAL WIPES, Byotrol Surface Sanitising Wipes, BYOTROL 4IN1 MULTI-PURPOSE SURFACE DISINFECTANT CLEANER, ENVOGENE HLD4E, ANIGENE HLD4V Disinfectant Cleaner. Its Medical Device Cleaning and Disinfection products include REPROZYME Enzymatic Instrument Cleaner and Trionic Wipes.
You don't have any saved screeners yet
